Loading...
  • Twitter
  • Facebook
  • Google
  • Twitter
  • Facebook
  • Google
fr

News

Invest Securities reste positive sur le géant franco-australien Unibail-Rodamco-Westfield, première foncière cotée de la planète dans l’immobilier commercial.
Le nouveau Peugeot 2008 passe à l’électrique. Lancée en fin d’année 2019, cette version dispose d’une autonomie confortable et de quelques spécificités. Toutes les infos.
Les moines de l'abbaye Saint-Sixte de Westvleteren, en Flandres, espère mettre fin au marché noir autour de sa fameuse bière.
Le Peugeot 2008 est mort, vive le nouveau 2008 ! Cette nouvelle génération du petit SUV de Peugeot évolue sur tous les plans. Nos premières impressions.
Ce n'est plus une légende, le Danemark fait partie des pays au monde où il fait bon vivre. Pour en avoir le coeur net, Ikea a décidé d'offrir un séjour à Copenhague de deux semaines à une personne.
Posté: il y a 3 heures
Europe’s industrial biotechnology sector is driving a massive change from petrochemical processes to more sustainable alternatives. Here are the top industrial biotechnology companies in Europe making...
Posté: Hier, 14:10
The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money...
Posté: Hier, 11:59
Phase II results from Dutch biotech CyTuVax show its enhanced hepatitis B vaccine reduces non-responders by 13%. Around 15% of people receiving vaccines for hepatitis B fail to produce antibodies that...
An anti-aging dietary supplement developed by the Swiss biotech Amazentis to combat age-related muscle weakening has improved the health of muscle cells in a first-in-human study. Mitochondria are par...
One of the greatest challenges faced by researchers in preclinical oncology studies is the translatability of animal models. Mimicking human diseases accurately to investigate the effects of novel the...
Artificial intelligence promises to use the power of data to solve some of the biggest problems of our time. But can it help us treat a disease as complex as cancer? Artificial intelligence and machin...
Zynteglo, a gene therapy developed by the US company bluebird bio for the treatment of beta-thalassemia, will cost European healthcare systems more than €1.5M per patient. Following the approval of th...
The hearing loss biotech Sensorion has issued bonds to raise €20M, which it will use to fund the phase II development for first-in-class drugs treating hearing loss and severe vertigo. The money will ...
DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over time, causing fewer side effects and helping patients stick to their treatment regimen. Mission:...
ADC Therapeutics has raised €67M ($76M) as part of a Series E round to fund the final push of an antibody-drug conjugate treatment for drug-resistant blood cancer into the market. With the latest fund...
Posté: Juin 11
Condition:   Type 1 Diabetes MellitusInterventions:   Drug: ADO09 formulation;   Drug: NovoRapid®Sponsor:   AdociaRecruiting
Posté: Juin 11
Condition:   Type 1 Diabetes MellitusInterventions:   Drug: ADO09 formulation;   Drug: NovoRapid®Sponsor:   AdociaRecruiting
Posté: Juin 11
Condition:   Type 1 Diabetes MellitusInterventions:   Drug: ADO09 formulation;   Drug: NovoRapid®Sponsor:   AdociaRecruiting
Condition:   Type 1 Diabetes MellitusInterventions:   Drug: ADO09 formulation;   Drug: Placebo;   Drug: Symlin®;   Drug: Humulin®;   Drug: Humalog®Sponsor:   AdociaCompleted
Posté: Janvier 30
Conditions:   Stage III Non-small Cell Lung Cancer;   UnresectableInterventions:   Drug: Durvalumab + Oleclumab;   Drug: Durvalumab;   Drug: Durvalumab + MonalizumabSponsor:   MedImmune LLCRecruiting
Posté: Janvier 7
Conditions:   Resectable;   Early-stage;   NSCLCInterventions:   Drug: Durvalumab;   Combination Product: Durvalumab + Oleclumab;   Combination Product: Durvalumab + Monalizumab;   Combination Product...
Posté: Mars 23 '17
Condition:   Carcinoma, Squamous Cell of Head and NeckInterventions:   Drug: Afatinib;   Drug: Palbociclib;   Drug: standard of care;   Drug: IPH2201Sponsor:   European Organisation for Research and T...
Condition:   Advanced Solid TumorsIntervention:   Combination Product: InterventionSponsor:   MedImmune LLCRecruiting
Posté: Septembre 11 '18
Condition:   Advanced Solid TumorsIntervention:   Biological: IPH5401 and DurvalumabSponsors:   Innate Pharma;   MedImmune LLCRecruiting
Posté: Septembre 11 '18
Condition:   Advanced Solid TumorsIntervention:   Biological: IPH5401 and DurvalumabSponsors:   Innate Pharma;   MedImmune LLCRecruiting
Pages : 1 2 3 4 »